Tinder Fungus as an Adjunct to Non-surgical Periodontal Therapy for Periodontitis (NCT07482878) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Tinder Fungus as an Adjunct to Non-surgical Periodontal Therapy for Periodontitis
Austria70 participantsStarted 2026-09
Plain-language summary
The goal of this interventional clinical study is to learn if a Tinder fungus-based formulation -specifically a toothpaste and oral supplement powder-works as adjuncts to non-surgical periodontal therapy (NSPT) in patients with periodontitis.
The main questions it aims to answer is:
• Does the Tinder fungus-based formulation as an adjunct to NSPT reduce bleeding on probing more than a commercially available toothpaste as an adjunct to NSPT? Researchers will compare tinder fungus toothpaste and oral powder as an adjunct to NSPT to a commercially available toothpaste as an adjunct to NSPT to see if the Tinder fungus-based formulation works as adjuncts to NSPT in patients with periodontitis.
Participants will:
* Take tinder fungus toothpaste and oral powder or a commercially available toothpaste as an adjunct to NSPT twice daily for 30 consecutive days
* Visit the clinic at least twice including a visit before and after the intervention
* Keep a diary documenting their well-being and the number of times they used the toothpastes in the morning and evening.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients diagnosed with Stage III or IV periodontitis
* Patients who have not yet initiated periodontal therapy
* Patients who have at least 20 remaining teeth
* Patients who are willing to use an electric toothbrush
* Patients who are willing to use interdental brushes
Exclusion Criteria:
* Patients who have previously received treatment for periodontitis
* Patients who have already undergone or initiated periodontal therapy
* Patients with a known allergy or intolerance to any component of the toothpaste or the powder
* Patients who are already using a product that contains tinder fungus (Fomes fomentarius)
* Patients who, at the time of periodontal treatment, are undergoing active systemic cancer therapy (e.g., chemotherapy or immunotherapy) or radiotherapy in the head and neck region, or for whom such therapy is planned. Previous illnesses or completed therapies do not constitute an exclusion criterion, provided that no current or planned treatment exists that could influence the periodontal treatment outcome or pose an increased risk for the participants.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Bleeding on probing (BoP in %) change
Timeframe: changes from baseline (T0; 1 day before intervention starts) to reevaluation (T1; 5 weeks (±1 week) after intervention start)